Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05038358

Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms

Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms: a Patient-derived Tumoroids Prospective Collection From Systemic Treatment Naive Tumors

Status
Recruiting
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
University Hospital, Grenoble · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that early development of chemoresistance mechanisms remains a major challenge. In order to better characterize these mechanisms, the aim is to develop a model of tumoroids derived from patients with a colorectal tumors prior to any systemic anti cancer treatment. This project will both allow us to study the role of the immunological microenvironment in chemoresistance and identify new predictive markers of tumor response. It will then serve to develop innovative personalized medicine strategies by targeting the newly identified mechanisms. This study should in fine help to improve the cancer patient's care.

Conditions

Timeline

Start date
2022-12-12
Primary completion
2028-09-30
Completion
2030-12-31
First posted
2021-09-09
Last updated
2025-04-20

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05038358. Inclusion in this directory is not an endorsement.